Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

Blood

Volumn 121, Issue 15, 2013, Pages 2975-2987

  G̈or̈gun, Güll̈u Topal ^a   Whitehill, Gregory ^a,b   Anderson, Jennifer L ^a,c   Hideshima, Teru ^a   Maguire, Craig ^a   Laubach, Jacob ^a   Raje, Noopur ^d   Munshi, Nikhil C ^a,e   Richardson, Paul G ^a   Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HAVERFORD COLLEGE   (United States)

^c MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD33 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; IXAZOMIB; LENALIDOMIDE; MELPHALAN; PANOBINOSTAT; PERIFOSINE; SALINOSPORAMIDE A; TANESPIMYCIN; THALIDOMIDE; VINCRISTINE; VORINOSTAT; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CYTOKINE; DRUG DERIVATIVE; IMMUNOLOGIC FACTOR; LIPOPOLYSACCHARIDE; PYRAZINE DERIVATIVE; REACTIVE OXYGEN METABOLITE;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER REGRESSION; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFECT; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LYMPHOCYTE; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; MYELOID DERIVED SUPPRESSOR CELLS; NEUTROPHIL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SUPPRESSOR CELL; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; CELL CULTURE; COCULTURE; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; PATHOLOGY; T LYMPHOCYTE; TUMOR CELL LINE; TUMOR VOLUME;

ANTIGENS, CD11B; ANTIGENS, CD15; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; IMMUNOLOGIC FACTORS; LIPOPOLYSACCHARIDES; MULTIPLE MYELOMA; MYELOID CELLS; PYRAZINES; REACTIVE OXYGEN SPECIES; SIALIC ACID BINDING IG-LIKE LECTIN 3; T-LYMPHOCYTES; THALIDOMIDE; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

MLCS; MLOWN;

EID: 84879452593     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-448548     Document Type: Article

References (49)

1. Görgün G, Anderson KC. Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer. Immunotherapy. 2011;3(10):1253-1264.
2. Görgün G, Calabrese E, Soydan E, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010;116(17):3227-3237.
3. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101(4):1530-1534. (Pubitemid 36182530)
4. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96(9): 2943-2950.
5. Mahindra A, Laubach J, Raje N, et al. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012; 9(3):135-143.
6. Hideshima T, Anderson KC. Novel therapies in MM: from the aspect of preclinical studies. Int J Hematol. 2011;94(4):344-354.
7. Mitsiades N, Mitsiades CS, Richardson PG, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003; 101(10):4055-4062. (Pubitemid 36857886)
8. Baitsch L, Fuertes-Marraco SA, Legat A, et al. The three main stumbling blocks for anticancer T cells. Trends Immunol. 2012;33(7):364-372.
9. Zhang B. Targeting the stroma by T cells to limit tumor growth. Cancer Res. 2008;68(23): 9570-9573.
10. Emens LA, Silverstein SC, Khleif S, et al. Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J Transl Med. 2012; 10:70.
11. Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, et al. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother. 2012;35(2):107-115.
12. Nagaraj S, Schrum AG, Cho HI, et al. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol. 2010;184(6): 3106-3116.
13. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10): 889-896.
14. Allavena P, Sica A, Garlanda C, et al. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev. 2008;222:155-161. (Pubitemid 351430369)
15. Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol. 2010;40(11): 2969-2975.
16. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166(1):678-689. (Pubitemid 32038493)
17. Diaz-Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49-59.
18. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-174.
19. Serafini P, Meckel K, Kelso M, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203(12):2691-2702. (Pubitemid 44833345)
20. Van Valckenborgh E, Schouppe E, Movahedi K, et al. Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow. Leukemia. 2012;26(11):2424-2428.
21. Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111(8):4233-4244.
22. Bronte V, Apolloni E, Cabrelle A, et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood. 2000;96(12): 3838-3846.
23. Kusmartsev S, Gabrilovich DI. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother. 2002;51(6): 293-298. (Pubitemid 34743981)
24. Lechner MG, Megiel C, Russell SM, et al. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med. 2011;9:90.
25. Kotsakis A, Harasymczuk M, Schilling B, et al. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods. 2012;381(1-2):14-22.
26. Dolcetti L, Marigo I, Mantelli B, et al. Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett. 2008;267(2):216-225.
27. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J. 2010;16(4):348-353.
28. Sica A, Schioppa T, Mantovani A, et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42(6):717-727.
29. Srivastava MK, Sinha P, Clements VK, et al. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010;70(1):68-77.
30. Obermajer N, Muthuswamy R, Lesnock J, et al. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood. 2011;118(20):5498-5505.
31. Obermajer N, Muthuswamy R, Odunsi K, et al. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 2011;71(24):7463-7470.
32. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother. 2010;59(10):1593-1600.
33. Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66(2):1123-1131. (Pubitemid 43165981)
34. Hoechst B, Ormandy LA, Ballmaier M, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008;135(1):234-243. (Pubitemid 351899008)
35. McMillin DW, Delmore J, Negri JM, et al. Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. Blood. 2012;119(15): e131-e138.
36. Daud AI, Mirza N, Lenox B, et al. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol. 2008; 26(19):3235-3241.
37. Filipazzi P, Valenti R, Huber V, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007;25(18):2546-2553. (Pubitemid 47041228)
38. Kusmartsev S, Su Z, Heiser A, et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008;14(24):8270-8278.
39. Poschke I, Mougiakakos D, Hansson J, et al. Immature immunosuppressive CD14+HLA-DR-/ low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010;70(11):4335-4345.
40. Vuk-Pavlović S, Bulur PA, Lin Y, et al. Immunosuppressive CD14+HLA-DRlow/-monocytes in prostate cancer. Prostate. 2010; 70(4):443-455.
41. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011;32(1):19-25.
42. Porembka MR, Mitchem JB, Belt BA, et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother. 2012; 61(9):1373-1385.
43. Lesokhin AM, Hohl TM, Kitano S, et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res. 2012;72(4): 876-886.
44. Prabhala RH, Pelluru D, Fulciniti M, et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010;115(26): 5385-5392.
45. Prabhala RH, Neri P, Bae JE, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood. 2006;107(1):301-304. (Pubitemid 43053555)
46. Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006;66(18): 9299-9307. (Pubitemid 44521152)
47. van Cruijsen H, van der Veldt AA, Vroling L, et al. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res. 2008;14(18):5884-5892.
48. -/CD15+/ CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2010;136(1):35-45.
49. -/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol. 2010;72(6):540-547.